MedTrace Logo

Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects

NCT02509845 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2019-08-01

No results posted yet for this study

Summary

The purpose of the clinical study is to evaluate the safety and bacterial impact of study drug (C16G2) administered in multiple oral gel doses to adolescent and adult dental subjects.

Conditions

  • Dental Caries

Interventions

DRUG

C16G2

Antimicrobial peptide

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Armata Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Mark Wolff, MD · New York University, School of Dentistry

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-02-29
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02509845 on ClinicalTrials.gov